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In order to gain entry into cells, diverse viruses, including Ebola virus, SARS-coronavirus and the emerg-
ing MERS-coronavirus, depend on activation of their envelope glycoproteins by host cell proteases. The
respective enzymes are thus excellent targets for antiviral intervention. In cell culture, activation of Ebola
virus, as well as SARS- and MERS-coronavirus can be accomplished by the endosomal cysteine proteases,
cathepsin L (CTSL) and cathepsin B (CTSB). In addition, SARS- and MERS-coronavirus can use serine pro-
teases localized at the cell surface, for their activation. However, it is currently unclear which protease(s)
facilitate viral spread in the infected host. We report here that the cysteine protease inhibitor K11777,
((2S)-N-[(1E,3S)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]-2-{[(E)-4-methylpiperazine-1-carbonyl]
amino}-3-phenylpropanamide) and closely-related vinylsulfones act as broad-spectrum antivirals by tar-
geting cathepsin-mediated cell entry. K11777 is already in advanced stages of development for a number
of parasitic diseases, such as Chagas disease, and has proven to be safe and effective in a range of animal
models. K11777 inhibition of SARS-CoV and Ebola virus entry was observed in the sub-nanomolar range.
In order to assess whether cysteine or serine proteases promote viral spread in the host, we compared the
antiviral activity of an optimized K11777-derivative with that of camostat, an inhibitor of TMPRSS2 and
related serine proteases. Employing a pathogenic animal model of SARS-CoV infection, we demonstrated
that viral spread and pathogenesis of SARS-CoV is driven by serine rather than cysteine proteases and can
be effectively prevented by camostat. Camostat has been clinically used to treat chronic pancreatitis, and
thus represents an exciting potential therapeutic for respiratory coronavirus infections. Our results indi-
cate that camostat, or similar serine protease inhibitors, might be an effective option for treatment of
SARS and potentially MERS, while vinyl sulfone-based inhibitors are excellent lead candidates for Ebola
virus therapeutics.
 2015 Published by Elsevier B.V.1. Introduction
Emerging viral diseases pose a unique risk to public health.
Ebola virus, severe acute respiratory syndrome coronavirus
(SARS-CoV) and members of the Henipavirus genus of paramyxovi-
ruses are all highly pathogenic viruses that have arisen in the past
40 years and caused, or threaten to cause, major outbreaks. Newviral threats continue to emerge, most recently demonstrated by
a novel beta-coronavirus, Middle East Respiratory Syndrome Coro-
navirus (MERS-CoV), which was identified in 2012 (Zaki et al.,
2012; Memish et al., 2013; de Groot et al., 2013). There are cur-
rently no approved vaccines or therapeutics for many of the highly
pathogenic viruses potentially dependent on cathepsins, including
Ebola virus, Nipah virus (NiV), MERS-CoV and SARS-CoV. Broad-
spectrum antiviral drugs, with overlapping therapeutic indications,
would facilitate rapid responses to new or changing pandemic
threats, potentially even without precise identification of the
agent. Targeting host factors involved in viral entry provides an
excellent avenue for such drug development, due to the limited
number of pathways involved (Zhou et al., 2011).
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Scheme 1. Synthesis of K11777 and P3-modified vinylsulfone analogs.
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tate viral entry into target cells by binding to receptors and by driv-
ing fusion of viral and host cell membranes. However, the
glycoproteins are synthesized as inactive precursors and depend
on activation by host cell proteases to acquire a fusion active form.
As a consequence, the respective enzymes are potential targets for
broad-spectrum antiviral intervention. Cell culture studies demon-
strated that endosomal cysteine proteases, in particular cathepsin
B (CTSB) and/or L (CTSL), can activate the glycoproteins of filovirus-
es, SARS-CoV, other coronaviruses, and NiV and Hendra (HeV)
viruses to facilitate entry into certain cell lines. In addition, activa-
tion of coronaviruses can also be accomplished by TMPRSS2, or
other serine proteases located at the cell surface, or secreted into
the extracellular space (Simmons et al., 2013). However, the
respective roles of endosomal and cell surface proteases in viral
spread in the infected host is unknown.
The development of protease inhibitors able to inhibit CTSL,
CTSB and related proteases would be an excellent starting point
for development of broad-spectrum antiviral therapies (Zhou
et al., 2011). We describe here the discovery of K11777 and its
related compounds, as broad-spectrum antivirals targeting endo-
somal proteases involved in viral entry. K11777, a cysteine prote-
ase inhibitor, blocked infection when viral entry did not require
activating serine proteases, as is the case with ebolavirus (EBOV).
K11777 also fully inhibited coronavirus infection, but only when
target cell lines lacking activating serine proteases were used. If
cells expressed cell-surface serine proteases known to activate cor-
onaviruses, both K11777 and a serine protease inhibitor, such as
camostat were required for full inhibition. Thus, both compounds
were deployed to examine which activation pathway is predomi-
nant in vivo. Camostat displayed antiviral activity in a pathogenic
animal model for SARS-CoV infection, indicating that serine prote-
ase inhibitors are suitable for treatment of SARS and potentially
MERS. The predicted effect of K11777 and related cysteine protease
inhibitors versus Ebola virus in vivomust await studies in approved
biocontainment facilities.2. Materials and methods
2.1. Libraries and commercial compounds
The cysteine protease inhibitor library screened in this work has
been described elsewhere (Ang et al., 2011). Briefly, the library
includes 2100 electrophilic cysteine protease inhibitors of vari-
ous chemotype (glycine nitriles, ketobenzoxazoles, ketooxadiaz-
oles, vinylsulfones, etc.), which were synthesized during the
course of industrial drug discovery programs targeting human
cathepsins (Palmer et al., 1995, 2005, 2006; Rydzewski et al.,
2002). Camostat mesylate, leupeptin, bafilomycin A1, ammonium
chloride, and chloroquine were purchased from Sigma–Aldrich.2.2. Synthesis of vinylsulfone cysteine protease inhibitors
K11777 and novel P3 derivatives were synthesized according to
the general approach described previously (Jaishankar et al., 2008)
and as illustrated here (Scheme 1). The N-substituted piperazines
were obtained from commercial sources or (for R = cyclopentyl
and cyclopropylmethyl) were prepared by reductive amination of
Boc-protected piperazine followed by treatment with HCl in
dioxane (51–53% over two steps). We find that the final coupling
of P3/P2 carboxylic acid to vinylsulfone amine is best accomplished
via the mixed anhydride, as this minimized epimerization of the
phenylalanine side chain. Final vinylsulfone analogs were >95%
pure as judged by LC/MS analysis. Characterization data for final
analogs is provided below.2.2.1. (2S)-N-[(1E,3S)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]-
2-{[(E)-4-ethylpiperazine-1-carbonyl]amino}-3-phenylpropanamide
(SMDC-256122)
1H NMR (400 MHz, CDCl3) d 7.93–7.91 (m, 2H), 7.78–7.68 (m,
1H), 7.68–7.58 (m, 2H), 7.37–7.25 (m, 8H), 7.16–7.14 (m, 2H),
6.90 (dd, J = 4.8, 15.2 Hz, 1H), 6.35–6.31 (m, 2H), 4.67 (br. S., 1H),
4.52 (d, J = 6.8 Hz, 1H), 4.13 (br. S., 3H), 3.50 (br. S., 2H), 3.39 (br.
S., 2H), 3.21–3.05 (m, 4H), 2.74–2.549 (m, 4H), 1.97–1.90 (m,
2H), 1.37 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) d 171.4,
156.6, 145.2, 140.1, 139.89, 136.4, 133.14, 130.14, 129.0, 128.9,
128.49, 128.29, 128.09, 127.3, 126.8, 125.9, 76.7, 76.4, 55.7, 54.2,
48.8, 47.8, 43.8, 37.8, 35.4, 31.4, 18.0; MS m/z = 589 [M+H]+.2.2.2. (2S)-N-[(1E,3S)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]-
2-{[(E)-4-(propan-2-yl)piperazine-1-carbonyl]amino}-3-
phenylpropanamide (SMDC-256123)
1H NMR (400 MHz, CDCl3) d 7.93–7.90 (m, 2H), 7.72–7.68 (m,
1H), 7.63–7.59 (m, 2H), 7.34–7.20 (m, 8H), 7.14–7.12 (m, 2H),
6.85 (dd, J = 4.8, 15.2 Hz, 1H), 6.69 (d, J = 8.2 Hz, 1H), 6.18 (dd,
J = 1.7, 15.1 Hz, 1H), 5.05 (d, J = 7.3 Hz, 1H), 4.68 (m, 1H), 4.56 (d,
J = 7.3 Hz, 1H), 3.45–3.28 (m, 4H), 3.10 (dd, J = 2.6, 7.3 Hz, 2H),
2.78–2.72 (m, 1H), 2.66–2.59 (m, 2H), 2.58–2.44 (m, 4H), 1.97–
1.91 (m, 1H) 1.85–1.81 (m, 1H) 1.08 (m, 6H); MSm/z = 603 [M+H]+.2.2.3. (2S)-N-[(1E,3S)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]-
2-{[(E)-4-propylylpiperazine-1-carbonyl]amino}-3-
phenylpropanamide (SMDC-256157)
1H NMR (400 MHz CDCl3) d = 7.85–7.83 (m, 2H), 7.67–7.61 (m,
1H), 7.55 (t, J = 7.6 Hz, 2H), 7.25–7.16 (m, 8H), 7.08 (d, J = 7.0 Hz,
2H), 6.79 (d, J = 4.8 Hz, 1H), 6.83 (d, J = 4.8 Hz, 1H), 6.16 (dd,
J = 1.6, 15.0 Hz, 1H), 5.56 (s, 1H), 5.19 (br. S., 1H), 4.62–4.60
(m, 1H), 4.47 (d, J = 7.5 Hz, 1H), 3.57–3.51 (m, 2H), 3.37–3.27 (m,
4H), 3.07 (d, J = 7.5 Hz, 2H), 2.65–2.48 (m, 2H), 2.37–2.22
(m, 6H), 1.93–1.72 (m, 3H), 1.52–1.39 (m, 4H), 0.93–0.85 (m,
3H); MS m/z = 603 [M+H]+.2.2.4. (2S)-N-[(1E,3S)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]-
2-{[(E)-4-phenylpiperazine-1-carbonyl]amino}-3-
phenylpropanamide (SMDC-256158)
1H NMR (400 MHz, CDCl3) d = 7.94–7.82 (m, 2H), 7.72–7.60 (m,
3H), 7.37–7.21 (m, 10H), 7.12 (d, J = 7.5 Hz, 2H), 7.00–6.96 (m, 3H),
6.87 (dd, J = 15.0 Hz, 4.4, 1H), 6.79 (d, J = 8.2 Hz, 1H), 6.19 (d,
J = 15.0 Hz, 1H), 5.23 (d, J = 7.1 Hz, 1H), 4.69–4.59 (m, 2H), 3.57–
3.49 (m, 4H), 3.17–311 (m, 6H), 2.66–2.57 (m, 2H), 295–1.78 (m,
2H); MS m/z = 637 [M+H]+.
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2-{[(E)-4-(2-methoxyethyl)piperazine-1-carbonyl]amino}-3-
phenylpropanamide (SMDC-256159)
1H NMR (400 MHz, CDCl3) d 7.84 (d, J = 7.9 Hz, 2H), 7.64
(t, J = 7.5 Hz, 1H), 7.55 (t, J = 7.7 Hz, 2H), 7.27–7.15 (m, 8H), 7.06
(d, J = 7.1 Hz, 2H), 6.78 (dd, J = 4.9, 15.1 Hz, 1H), 6.61
(d, J = 8.4 Hz, 1H), 6.17 (d, J = 15.0 Hz, 1H), 5.74 (d, J = 6.8 Hz, 1H),
4.59 (d, J = 4.2 Hz, 1H), 4.40 (q, J = 7.6 Hz, 1H), 3.71–3.69 (m, 3H),
3.49 (br. S., 3H), 3.32 (s, 3H), 3.16–3.14 (m, 2H), 3.06–2.8 (m,
4H), 2.65–2.51 (m, 4H), 1.89–1.79 (m, 2H); 13C NMR (75 MHz,
CDCl3) d 172.6, 156.7, 146.1, 140.4, 139.8, 137., 133.6, 130.3,
129.3, 129.1, 128.5, 128.5, 128.3, 127.4, 127.0, 126.2, 77.4, 76.6,
66.5, 58.8, 57.2, 56.4, 52.1 49.2, 41.1, 35.22, 31.8; MS m/z = 619
[M+H]+.
2.2.6. (2S)-N-[(1E,3S)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]-
2-{[(E)-4-tert-butylpiperazine-1-carbonyl]amino}-3-
phenylpropanamide (SMDC-256160)
1H NMR (400 MHz, CDCl3) d = 7.84–7.82 (m, 2H), 7.64–7.61 (m,
1H), 7.58–7.52 (m, 2H), 7.27–7.14 (m, 8H), 7.08–7.03 (m, 2H), 6.87
(br. S., 1H), 6.79 (dd, J = 4.8, 15.2 Hz, 1H), 6.22 (d, J = 15.0 Hz, 1H),
5.99 (br. S., 1H), 4.61–4.59 (m, 1H), 4.41 (d, J = 7.5 Hz, 1H), 4.07–
3.96 (m, 2H), 3.49–3.36 (m, 4H), 3.12–2.98 (m, 2H), 2.68–2.45
(m, 2H), 2.68–2.45 (m, 4H), 1.88–1.80 (m, 2H), 1.34 (s, 9H); MS
m/z = 617 [M+H]+.
2.2.7. (2S)-N-[(1E,3S)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]-
2-{[(E)-4-cyclopentylpiperazine-1-carbonyl]amino}-3-
phenylpropanamide (SMDC-256161)
1H NMR (400 MHz, CHLOROFORM-d) d = 7.84–7.81 (m, 2H),
7.65–7.61 (m, 1H), 7.56–7.52 (m, 2H), 7.28–7.14 (m, 8H), 7.09–
7.07 (m, 2H), 7.01 (br. S, 1H), 6.80 (dd, J = 4.7, 15.1 Hz, 1H), 6.24–
6.20 (m, 1H), 6.06 (br. S., 1H), 4.61–4.59 (m, 1H), 4.42 (q,
J = 7.5 Hz, 1H), 3.99 (t, J = 16.1 Hz, 2H), 3.48–3.33 (m, 4H), 3.13–
2.97 (m, 3H), 2.64–2.52 (m, 4H), 2.42 (br. S., 1H), 1.97–1.78 (m,
8H); MS m/z = 629 [M+H]+.
2.2.8. (2S)-N-[(1E,3S)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]-
2-{[(E)-4-(cyclopropylmethyl)piperazine-1-carbonyl]amino}-3-
phenylpropanamide (SMDC-256162)
1H NMR (400 MHz, CDCl3) d 7.83–7.81 (m, 2H), 7.65–7.61 (m,
1H), 7.55–7. 51 (m, 2H), 7.25–7.15 (m, 8H), 7.06–7.04 (m, 3H),
6.80 (dd, J = 4.8, 15.0 Hz, 1H), 6.23 (dd, J = 1.6, 15.0 Hz, 1H), 6.12
(br. D., J = 6.8 Hz, 1H), 4.60–4.59 (m, 1H), 4.42 (d, J = 7.5 Hz, 1H),
4.02 (br. S., 2H), 3.53 (br. S., 2H), 3.34 (br. S., 2H), 3.11–2.97 (m,
2H), 2.80 (d, J = 7.1 Hz, 2H), 2.68–2.48 (m, 4H), 1.87–1.79 (m,
2H), 1.04–0.97 (m, 1H), 0.73–0.68 (m, 2H), 0.31 (m, 2H); MS
m/z = 615 [M+H]+.
2.3. Cell lines and reagents
Human Embryonic Kidney 293 cells, 293T cells, clone 17 (293T/
17), and Vero cells were obtained from American Type Culture Col-
lection (ATCC), while the Huh7.5 cell line was a gift from Apath
LLC. All cells were grown in Dulbecco’s Modified Eagle Medium
(DMEM; Invitrogen) supplemented with 10% FBS and Penicillin
and Streptomycin (10 U/ml). 293T/17 stably expressing ACE2
(293T/ACE2) were established by transfecting 293T/17 cells with
pcDNA6 (Invitrogen) encoding the ACE2 gene and selecting for sta-
ble transformants using blasticidin S (2.5 lg/ml). 293 stably
expressing human CD13 [also called aminopeptidase N (APN)]
(293/CD13) were established by transfecting cells with pcDNA3
(Invitrogen) encoding the CD13 gene and selecting for stable trans-
formants using geneticin 418 (2.0 mg/ml). Expression of CD13 was
measured with flow cytometric analysis.2.4. Plasmids and gene constructs
Lentiviral pseudotypes were generated from two plasmids, one
encoding the envelope and the second an envelope-deficient HIV
reporter construct – either pNL4-3 Luc-R-E- (pNL-luc) or pNL4-
3.REN.R-E- (Zhou et al., 2011; Connor et al., 1995). Plasmids encod-
ing spike (S) proteins from human coronaviruses SARS-CoV, NL63
and 229E, MERS-CoV, glycoproteins (GP) from filoviruses EBOV
(formerly known as ebolavirus Zaire), Sudan ebolavirus (SUDV),
Tai Forest ebolavirus (TAFV), Reston ebolavirus (RESTV), and Mar-
burg (MARV), as well as NiV F and G, Lassa virus GP, vesicular sto-
matitis virus (VSV) G protein, chikungunya virus (CHIKV) E1/E2,
and MLV envelope, have been described (Zhou et al., 2011, 2012;
Simmons et al., 2005, 2004, 2002; Salvador et al., 2013, 2009). Bun-
dibugyo ebolavirus (BEBOV) GP was a gift from Edward Wright
(University of Westminster). HCV E1E2 was synthesized (Gen-
script, CA) while Junin virus G protein was a gift from Sean Amberg
(Siga Technologies, OR). Plasmids encoding cellular type II trans-
membrane serine proteases (TTSP) TMPRSS2 were previously
described (Glowacka et al., 2011).
2.5. Pseudovirion production and titration
Lentiviral pseudovirions were produced essentially as previ-
ously described (Zhou et al., 2010). Briefly, 293T/17 cells were
transfected with up to 30 lg of viral envelope encoding plasmid
and 10 lg of pNL4-3 reporter backbone per 10-cm dish by calcium
phosphate transfection. The next day, expression was induced with
sodium butyrate (10 mM) for 6 h before washing once. Forty hours
after transfection, supernatant was filtered through a 0.45 lm-
pore-size filter and frozen at 80 C. Virus was titrated essentially
as it would be used in the screening assay. If required, virions were
purified and concentrated by ultracentrifugation (28,000 rpm in a
SW28 rotor, Beckman) over a 20% sucrose cushion, resuspended
in Hank’s balanced salt solution (HBSS) and stored at 80 C as ali-
quots. Pseudoviruses were normalized for equal infectivity by
transduction of target cells with serially diluted stock followed
48 h later by determination of luciferase activity in cell lysates
according to the manufacturer’s instruction (Promega). VSV-based
pseudotypes bearing Junin virus G were produced essentially as
described (Steffen et al., 2013) by transfecting 293T cells with
16 lg of Junin G plasmid and then infecting the cells with recombi-
nant VSVDG-GFP(VSV-G). Progeny VSVDG-GFP(Junin-G) virus was
then collected, titrated and used for inhibition studies. In the case of
NiV, VSVDG-GFP(NiV F/G) viruses were produced via calcium phos-
phate transfection of 293T cells with 10 ug of NiV F and 10 lg of NiV
G. Transfected cells were left for 16 h before an initial medium
change; then infected with recombinant VSVDG-GFP(VSV-G)
(MOI 0.1–0.3) after five additional hours. Media alone or compound
of interest were then added at the desired concentration and cells
were incubated overnight before supernatant was harvested and
filtered. To assay for inhibition, production of entry-competent
virus was examined. Target cells were pre-plated at 25,000 cells/
50 ll in 96 well plates and allowed to attach overnight. 50 ll of
undiluted VSVDG-GFP NiV F/G made in the presence or absence
of inhibitor was added. Cells were incubated at 37 C with 5% CO2
for two days, and thenwashed and fixedwith 2% paraformaldehyde
and GFP fluorescence determined by flow cytometry using a Becton
Dickinson LSRII cytometer and FlowJo software. 100% infection was
determined with samples infected with pseudovirons produced
from cells with no compound exposure.
2.6. Screening assays
High-throughput screens for viral entry inhibitors were per-
formed in 384-well plates using the dual-envelope pseudotype
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were diluted in DMEM with 10% FBS to 50 lM (5% DMSO) and
10 ll were transferred to 384-well white tissue culture plates
(NUNC) using a Biomek FX-P (Beckman-Coulter). A mixture of
the target virus [e.g., (HIV-luc(SARS-CoV S)) and the control virus
[HIV-ren(Lassa GP) or HIV-ren(MLV Env)] was made, with the con-
centration and ratio derived empirically to give similar robust lev-
els of reporter expression. 10 ll of reporter virus mix was added to
each well using a Matrix Well-Mate (Thermo Scientific). 30 ll of
cells (170,000 cells per milliliter) were then added to all wells.
Plates were incubated for two days at 37 C/5% CO2 and firefly
and renilla luciferase reporter expression was determined using
the Dual-Glo luciferase assay substrate (Promega).
2.7. Dose response curves
Assays for dose response curves were performed in 96-well
white tissue culture plates (NUNC). Target cells were pretreated
with test compounds or inhibitors serially diluted in medium, fol-
lowed by either a single virus or a two reporter virus mixture,
depending on the purpose of the assay. The env/reporter combina-
tions were reversed in order to demonstrate inhibition was not
directed at the backbone or reporter enzyme rather than entry.
Plates were incubated for two days at 37 C/5% CO2 and firefly
and renilla luciferase reporter expression was determined using
the Dual-Glo luciferase substrate (Promega), or detection of firefly
luciferase reporter expression using the Bright-Glo™ luciferase
substrate (Promega). The infectivity for pseudotyped VSVs with
NiV F/G was analyzed by measuring the number of GFP expressing
cells by flow cytometric analysis.
2.8. Dual inhibition study
Either Caco2 or 293-CD13 cells transiently expressing TMPRSS2
were pretreated with serially diluted K11777, a combination of
serially diluted K11777 and camostat mesylate at 1 or 10 lM or
a combination of serially diluted camostat mesylate and K11777
at 2.5 lM for 60 min at 37 C and then incubated with infectiv-
ity-normalized pseudoviruses in the presence of the inhibitors.
The cells were then cultured at 37 C/5% CO2 for two days and lucif-
erase expression was measured.
2.9. Live SARS-CoV assays and cytotoxicity
Antiviral replication with Urbani and Toronto-2 strains of live
SARS-CoV, as well as cytotoxicity of selected compounds was
investigated using three in vitro assays, cytopathic effect (CPE)
inhibition assay, neutral red (NR) uptake assay, and virus yield
reduction assay as described in Kumaki et al. (2011).
For cell viability assays, cells were seeded in 96-well black tis-
sue culture plates (Costar) and treated with compounds with final
concentration of 1% DMSO. The quantity of the ATP present in
metabolically active cells was determined with CellTiter-Glo
luminescent cell viability assay kits (Promega, Madison, WI).
2.10. Camostat and SMDC256160 in mice
SMDC256160 (50 mg/kg), camostat (30 mg/kg) alone,
SMDC256160 (50 mg/kg) combined with camostat (30 mg/kg), or
negative control (water) were administrated into 6–8 week old
female BALB/c mice by oral gavage twice a day for 9 days beginning
10 h prior to virus exposure. Ten mice were assigned to each group.
The Texas Biomedical Research Institute’s institutional (Texas
Biomed) animal care and use committee approved all animalprotocols. Live virus assays were performed at the ABSL-4 facility
at Texas Biomed using a mouse adapted strain of SARS-CoV
(MA15) kindly provided by Ralph Baric (University of North Caro-
lina). Mice were infected by administering 10,000 pfu of virus by
intranasal instillation.
2.11. Data analysis
Statistical calculations were performed in Excel (Microsoft,
Seattle, WA). Compounds from the primary screens were consid-
ered inhibitory when the luciferase readings of SARS-CoV, but
not the internal control pseudotyped viruses, fell below the pre-
defined cut-off, mean-3  SD (m-3SD). IC50 (50% inhibitory concen-
tration) and CC50 (50% cell cytotoxic concentration) values were
calculated using non-linear regression analysis based on the sig-
moidal dose response equation using PRISM 6 (GraphPad Software
Inc) (applied to the percent inhibition and concentration data.
A selectivity index (SI) was calculated using the formula
SI = CC50/IC50.3. Results
3.1. Discovery of the broad-spectrum antiviral K11777
We recently developed an internally-controlled dual virus HTS
assay for identification of inhibitors of viral entry (Zhou et al.,
2011). Using SARS-CoV entry assays, we screened a library of
2100 cysteine protease inhibitors with confirmed activity against
human cathepsins. Unsurprisingly, a large number of hits were
identified. Upon validation of the hits, the most robust activity
was observed for K11777 ((2S)-N-[(1E,3S)-1-(benzenesulfonyl)-
5-phenylpent-1-en-3-yl]-2-{[(E)-4-methylpiperazine-1-carbonyl]
amino}-3-phenylpropanamide) (Fig. 1a), a compound known to
inhibit cruzain, a cathepsin-L like protease from the protozoan par-
asite Trypanosoma cruzi (Engel et al., 1998). In addition, K11777
inhibits a variety of cysteine proteases, including human cathepsins
(Choy et al., 2013) and cathepsin-like proteases from several other
parasites (Ndao et al., 2013; Abdulla et al., 2007).
To determine whether K11777 can inhibit entry driven by other
viral envelope proteins, HIV-based pseudotypes bearing spikes from
coronaviruses (SARS-CoV, HCoV-229E, NL63, MERS-CoV) or glyco-
proteins from filoviruses (EBOV, SUDV, TAFV, RESTV, BEBOV and
MARV) were examined together with control pseudotypes. We also
tested the ability of K11777 to prevent activation and hence infec-
tivity during production of VSV-based pseudotypes (Salvador
et al., 2009) bearing NiV F and G. K11777 was active against all
the major enveloped viruses previously known to require cathep-
sin-mediated proteolysis, including a variety of coronaviruses and
filoviruses, especially EBOV (Fig. 1b; Table 1). K11777 inhibited
SARS-CoV pseudovirus entry with an IC50 of 0.68 nM (Fig. 1b,
Table 1) while no toxicity was observed, CC50 > 10 lM (data not
shown). MERS-CoV and NL63 envelope required higher concentra-
tions of K11777 for inhibition, likely due to less reliance on CTSL
(Gierer et al., 2013; Hofmann et al., 2006). Nevertheless, the IC50s
were very low: 46 nM for MERS-CoV and <7 nM for NL63. In con-
trast, 100 nM K11777 did not inhibit infection mediated by enve-
lope glycoproteins from an alphavirus (CHIKV), a rhabdovirus
(VSV), a flavivirus (HCV), the retroviruses MLV-A and XMRV or
two arenaviruses, Lassa and Junin virus.
3.2. Alternative proteases for entry
Coronaviruses including SARS-CoV, human coronavirus 229E
(hCoV-229E) and MERS-CoV use two distinct pathways for cell
Fig. 1. Identification of protease inhibitor K11777 as a broad-spectrum antiviral
drug candidate. (a) Structure of K11777; N-methyl-piperazine-phenylalanyl-hom-
ophenylalanyl-vinylsulfone phenyl. (b) Dose response curves of compound K11777
against pseudoviruses with a variety of different viral envelopes. Data shown as
mean ± SD of triplicate measurements. Representative experiments of at least three
experiments are shown.
80 Y. Zhou et al. / Antiviral Research 116 (2015) 76–84entry: (i) the endosomal pathway, in which spike activation is
facilitated by the pH-dependent endosomal protease CTSL; or (ii)
entry at the plasma membrane, which relies on spike activation
by secreted or surface proteases – such as trypsin and type II trans-
membrane serine proteases HAT (human airway trypsin-like pro-
tease) or TMPRSS2 (Gierer et al., 2013; Bertram et al., 2011,
2013). The serine protease inhibitor camostat mesylate (camostat)
inhibits the enzymatic activity of TMPRSS2 and other cell-surface
proteases involved in coronavirus activation (Kawase et al.,
2012). We therefore assessed whether K11777 displays antiviralTable 1
K11777 inhibits entry of a variety of enveloped viruses.
Pseudoviruses Family
SARS-CoV Coronaviridae
HCoV-229E Coronaviridae
NL63 Coronaviridae
MERS-CoV Coronaviridae
Zaire ebolavirus (EBOV) Filoviridae
Sudan ebolavirus (SUDV) Filoviridae
Tai Forest ebolavirus (TAFV) Filoviridae
Reston ebolavirus (RESTV) Filoviridae
Bundibugyo ebolavirus (BEBOV) Filoviridae
Marburg (MARV) Filoviridae
Nipah Paramyxoviridae
Chikungunya Togaviridae
Vesicular stomatitis Rhabdoviridae
Amphotropic murine leukemia Retroviridae
Xenotropic murine leukemia Retroviridae
Lassa Arenaviridae
Junin Arenaviridae
HCV (H77 envelope) genotype 1a Flaviviridae
a IC50 (inhibitory concentration) values are the concentrations required to inhibit the i
dose response curves. All envelopes apart from Nipah and Junin were used to make HIV-
were then pretreated with serial dilutions of K11777 and exposed to virus. VSV-based p
envelope, and transducing with VSVDG(GFP)-G. Progeny virus was then collected and t
response equation was applied to the percent inhibition and concentration data. Dat
representative of at least two independent experiments.activity in TMPRSS2 expressing cells. For this, we incubated target
cells with camostat, K11777, or a combination of K11777 and
camostat and then infected with pseudoviruses bearing 229E-S.
K11777 alone demonstrated up to 70% inhibition of 229E-S-med-
iated transduction. Simultaneous treatment with camostat and
K11777 increased inhibition to 90% (Fig. 2a, left panel). Similar
inhibition patterns were obtained using the human intestinal epi-
thelial cell line Caco-2, which express endogenous TMPRSS2 and
cathepsins (Fig. 2b). In contrast, K11777 alone fully blocked Ebola
pseudovirus infection, while camostat had no impact on viral
infection (Fig. 2a, middle panel). Finally, treatment of cells with
K11777, camostat or both, had no impact on VSV-G driven viral
entry (Fig. 2a, right panel), which is known to be independent of
cysteine and serine protease activity. These results indicate that
both serine and cysteine proteases can activate 229E-S for viral
entry, as expected, while EBOV-GP exclusively relies on cysteine
proteases for activation.3.3. In vitro antiviral activity of new vinylsulfone analogs
We next synthesized a series of K11777 analogs to further
explore the antiviral activity of vinylsulfone-class protease inhibi-
tors (Table 2). Given that the piperazine ring in K11777 is basic
(pKa 7.8 for the conjugate acid) we considered that the com-
pound might accumulate in the acidic (lysosomal and endosomal)
compartments where target proteases such as CTSL and CTSB are
abundant. To explore this notion and to more generally evaluate
structure–activity trends, we synthesized new vinylsulfone ana-
logs in which the substituent on the piperazine ring nitrogen atom
was modified systematically. While the majority of these analogs
(Table 2) retain a basic piperazine ring, the N-phenyl analog
SMDC-256158 is only weakly basic (pKa 3.42 for the conjugate
acid) and thus will be neutral at physiological pH and would not
be expected to exhibit lysosomotropic behavior. Nearly all of the
new analogs possessed potency comparable or superior to
K11777 against SARS-CoV and EBOV (Table 2), the most potent
analogs being SMDC256122 (SARS-CoV IC50 = 0.04 nM; EBOV
IC50 = 0.12 nM), SMDC256159 (SARS-CoV IC50 = 0.07 nM; EBOV
IC50 = 0.16 nM) and SMDC256160 (SARS-CoV IC50 = 0.08 nM;
EBOV IC50 = 0.11 nM).Genome type Cells IC50 (nM)a
ssRNA(+) 293T-ACE2 0.68 ± 0.09
ssRNA(+) 293T-CD13 1.48 ± 0.13
ssRNA(+) 293T-ACE2 6.78 ± 0.24
ssRNA(+) Vero 46.12 ± 6.63
ssRNA() 293T 0.87 ± 0.06
ssRNA() 293T 1.14 ± 0.07
ssRNA() 293T 2.26 ± 0.10
ssRNA() 293T 3.37 ± 0.29
ssRNA() 293T 5.91 ± 0.50
ssRNA() 293T 1.90 ± 0.16
ssRNA() 293T 0.42 ± 0.03
ssRNA(+) 293T >100
ssRNA() 293T >100
ssRNA()RT 293T >100
ssRNA()RT 293T >100
ssRNA() 293T >100
ssRNA() Vero >100
ssRNA(+) Huh7.5 >100
nfectivity of the pseudotyped viruses on cells by 50%, which were determined from
based pseudotypes. Target cells (293T, 293T expressing ACE2 or CD13, or Vero cells)
seudotypes were made by transfecting cells with Nipah F and G plasmids, or Junin
itered on target cells. A non-linear regression analysis based on the Sigmoidal dose
a is shown as means of triplicate measurements ± standard deviation. Values are
Fig. 2. Inhibition of serine and/or cysteine proteases in cells transfected with, or endogenously expressing, TMPRSS2. 293T-CD13 cells transiently expressing TMPRSS2 (a) or
Caco2 cells (b) were pretreated with serially diluted compound K11777, or a combination of serially diluted K11777 and camostat at two different concentrations (1 or
10 lM), followed by incubation with infectivity-normalized pseudoviruses in the presence of the inhibitors. The cells were then cultured at 37 C/5% CO2 for two days and
luciferase expression was measured. (a) Simultaneous treatment with both K11777 and camostat for 229E-S, EBOV or VSV-G pseudovirus infection. (b) Enhanced inhibition
by a combination of K11777 and camostat for 229E-S mediated viral entry using Caco2 cells.
Table 2
Structure and antiviral activity of K11777 analogs modified at the P3 position.
H
N S
Ph
O O
PhO
N
H
O
N
N
R
Compound P3 substituent
R=
MW pKaa HIV-luc
(SARS-CoV S)b
IC50 (nM)
HIV-luc
(EBOV GP)
IC50 (nM)
K11777 Me 575 7.02 0.32 ± 0.02 0.36 ± 0.02
SMDC-256122 Et 589 7.29 0.04 ± 0.01 0.12 ± 0.01
SMDC-256123 i-Pr 603 7.57 0.11 ± 0.01 0.25 ± 0.07
SMDC-256157 n-Pr 603 7.59 0.24 ± 0.03 0.42 ± 0.03
SMDC-256158 Ph 637 3.42 2.49 ± 0.34 2.69 ± 0.43
SMDC-256159 ACH2CH2OCH3 619 6.82 0.07 ± 0.02 0.16 ± 0.02
SMDC-256160 t-Bu 617 7.87 0.08 ± 0.01 0.11 ± 0.03
SMDC-256161 Cyclopentyl 629 8.01 0.25 ± 0.16 0.18 ± 0.01
SMDC-256162 Cyclopropylmethyl 615 7.73 0.16 ± 0.03 0.10 ± 0.01
a Calculated in MarvinSketch 5.5.0.1 from ChemAxon Ltd.
b IC50 (inhibitory concentration) values of SARS-CoV or EBOV are the concentrations required to inhibit the infectivity of SARS-CoV or EBOV pseudotyped viruses on 293T-
ACE2 cells by 50%, which were determined from dose response curves. A non-linear regression analysis based on the Sigmoidal dose response equation was applied to the
percent inhibition and concentration data. Data is shown as means of quadruplicate measurements ± standard deviation. Values are representative of at least three inde-
pendent experiments.
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weakly basic analog SMDC-256158 was 10–100-fold less potent
than the other basic and protonatable vinylsulfone analogs
(Table 2). The reduced potency of SMDC-256158 is likely not
related to the size of the phenyl substituent, since even larger,
biaryl P3 substituents are known to be well tolerated in cathep-
sin-L like proteases such as cruzain (Beaulieu et al., 2010). Also
consistent with this interpretation, we find that other bulky tert-
butyl and cyclopentyl groups are tolerated in analogs like SMDC-
256160 and SMDC-256161. Therefore, the most likely explanationis that as a weak base and the only analog expected not to be pro-
tonated at physiological pH, SMDC-256158 does not accumulate in
the lysosome to the same extent that the other, more basic, analogs
do. Conversely, K11777 and the other basic analogs accumulate in
acidic endosomal compartments where target cysteine proteases
such as CTSL and CTSB are located.
To further verify the antiviral effects of three of the most effi-
cient drug candidates, inhibition assays were carried out with two
strains (Urbani and Toronto-2) of replication competent SARS-
CoV, and using two separate readouts of replication (summarized
82 Y. Zhou et al. / Antiviral Research 116 (2015) 76–84in Table 3). IC50 values ranged from <0.05 to 0.52 lM for K11777,
<0.48 to <2.26 lM for SMDC256159, and <0.05 to 0.32 lM for
SMDC256160. Furthermore, 90% reduction in viral yields of
0.35–1.04 lM (K11777), <0.48–7.1 lM (SMDC256159) and 0.49–
12.2 lM (SMDC256160) were observed. We also performed studies
with authentic hCoV-229E and determined the IC50 for all three
compounds to be approximately 0.2 lM (data not shown). For the
three compounds CC50’s were all above 25 lM. The selective indices
(SI, CC50/IC50) ranged from 94.5 (SMDC256159 inhibition against
the Toronto-2 strain) to over 1000. Thus, these compounds were
identified as ideal tools to determine whether cysteine or serine
proteases promote SARS-CoV spread in the host.Fig. 3. Effects of per os administered SMDC256160 and/or camostat on survival of
BALB/c mice infected with a lethal SARS-CoV. Ten mice per group were dosed twice
a day by oral gavage with SMDC256160 and/or camostat or diluent alone (sterile
water) for 9 days beginning 10 h prior to infection with 10,000 pfu of mouse-
adapted SARS-CoV.3.4. Evaluating the efficacy of SMDC256160 in a lethal SARS-CoV BALB/c
mouse model
The pharmacokinetics and bioavailability of SMDC256159 and
SMDC256160 in male and female Sprague–Dawley rats were
determined following a single i.v. or p.o. dose administration (data
not shown) and demonstrated similar profiles to K11777 (Jacobsen
et al., 2000).
In initial experiments, the antiviral efficacy of low-dose (1–
10 mg/kg) SMDC256160was examined in a lethal SARS-CoVmouse
model (Day et al., 2009).While therewas a trend toward protection,
there was no statistically significant reduction in mortality or dis-
ease severity (data not shown). Experiments were therefore
repeated at higher doses of cysteine protease inhibitor (50 mg/kg),
either alone or in combination with the serine protease inhibitor,
camostat (30 mg/kg) (Fig. 3). SMDC-256160 alone was no more
effective than vehicle treated controls (Fig. 3). In contrast, camostat
was effective in protecting mice against death due to a lethal infec-
tion by SARS-CoV, with a survival rate of 60%. Combining both
classes of inhibitors did not significantly improve survival versus
camostat alone. Thus, SARS-CoV depends on serine protease activity
for viral spread in vivo.4. Discussion
Viral entry is a multi-step process and an attractive target for
antivirals (Zhou and Simmons, 2012). The fact that disparate path-
ogenic viruses such as SARS-CoV, EBOV and NiV all utilize a com-
mon host factor for entry – CTSL – suggested that inhibitors of
cathepsins might have broad applicability. Cysteine proteases have
proved to be druggable targets and their inhibitors are generally of
low toxicity.
We screened a library of drug-like compounds with established
activity against CTSL and CTSB for activity against SARS-CoV and
filoviruses, including EBOV. We describe here the confirmationTable 3
Inhibition of live SARS-CoV replication in Vero 76 cells.
Compound Virus strain CPE inhibition
IC50a (lM) CC50b (lM) SIc
K11777 Urbani <0.05 ± 0 >105.6 ± 59.3 >2112
Toronto-2 <0.05 ± 0 85.2 ± 0 >1704
SMDC256159 Urbani 0.65 ± 0.81 >109.2 ± 49.8 >168
Toronto-2 <0.48e 85.6 >178.3
SMDC256160 Urbani <0.08 ± 0.05 50.6 ± 26.7 >632.5
Toronto-2 <0.05 27.6 >552
a 50% virus inhibitory concentration.
b 50% cell cytotoxic concentration of drug.
c Selective index: SI = CC50/IC50.
d 90% virus inhibitory concentration.
e No SDs were reported when n 6 2.that protease inhibitors, such as K11777 and related compounds,
are broad-spectrum antiviral drug candidates targeting viral entry.
A number of additional vinylsulfone analogs were synthesized,
some of which exhibited enhanced potency compared to K11777.
Most notably, potent antiviral activity was correlated with the
presence of a basic piperazine ring at the P3 position, a finding that
is consistent with accumulation in endosomal (acidic) compart-
ments where the target cysteine proteases required for viral entry
are located. The vinylsulfones described herein were broadly active
against viral entry for three viral families: the corona-, filo- and
paramyxoviruses, and are very well tolerated in vivo (Barr et al.,
2005).
The notion that coronaviruses, including SARS-CoV, use both a
cathepsin-dependent endosomal pathway and a direct cell-surface
serine protease-mediated pathway for entry (Simmons et al., 2013)
is supported by our finding that the combination of K11777 and
camostat was superior to either compound alone. In contrast, EBOV
infection was effectively inhibited by K11777, but not by camostat.
While unidentified additional proteases have been reported to
mediate infection by other filoviruses, such as MARV (GnirssNeutral red (NR) assay Virus yield reduction
IC50a (lM) CC50b (lM) SIc IC90d (lM)
0.52 ± 0.17 >100.3 ± 64.2 >192.9 0.35 ± 0.35
0.35 ± 0.17 52.7 ± 7.8 150.6 1.04 ± 1.22
<2.26 ± 3.56 >91.6 ± 65.6 >40.5 7.1 ± 7.6
0.65 61.4 94.5 <0. 48
<0.13 ± 0.03 >81.8 ± 58.5 >629.2 0.49 ± 0
0.32 30.8 96.3 12.2
Y. Zhou et al. / Antiviral Research 116 (2015) 76–84 83et al., 2012) and SUDV (Misasi et al., 2012), efficient inhibition by
the vinylsulfone analogs suggests that the unidentified proteases
are cysteine proteases related to CTSB and L. Activation of NiV
and HeV appears to be fully dependent on CTSL and/or CTSB
(Pager et al., 2006; Diederich et al., 2008, 2012). Thus, vinylsulfones
are promising antiviral lead compounds for further optimization as
potent inhibitors of these two important groups of pathogenic
emerging viruses, including EBOV.
Previous reports showed that compound K11777 and analogs
have satisfactory safety and pharmacokinetic profiles in rodents,
dogs and primates (Abdulla et al., 2007). The fact that K11777, as
a vinylsulfone, is an irreversible and not highly selective cysteine
protease inhibitor does not appear to be a liability, at least if it is
used as a short course antiviral. Indeed, in the case of filoviruses,
the lack of target selectivity is likely a boon – increasing effective-
ness by also inhibiting secondary proteases (Gnirss et al., 2012;
Misasi et al., 2012).
The availability of a novel, highly potent and largely non-toxic
cysteine protease inhibitor, SMDC256160, afforded the opportu-
nity to assess whether the activity of cysteine or serine proteases
is required for viral spread in vivo. For this, a mouse model for
lethal SARS-CoV infection was employed. Notably, only inhibition
of serine proteases mitigated SARS-CoV pathogenesis in vivo. Thus,
future development of anti-coronavirus therapeutics should focus
on inhibiting serine rather than cysteine proteases, with camostat
being an excellent starting candidate. Indeed, in Japan camostat is
used clinically, particularly to treat chronic pancreatitis (Ikeda
et al., 1988; Sai et al., 2010), with a reasonable safety profile
(Fiopan Tablets, 2009).
5. Conclusions
Our results showed that targeting viral entry, and more specif-
ically, the endosomal proteolysis step of entry, is an attractive
strategy to discover new antiviral agents – particularly for filovi-
ruses, like EBOV, and some paramyxoviruses. Although endosomal
and cell-surface proteases can facilitate coronavirus entry in cul-
tured cells, only the activity of serine proteases is required for viral
spread in the infected host. Nevertheless, the highly potent cys-
teine protease inhibitors identified here might be excellent starting
points for the development of highly effective inhibitors of Ebola
virus and Paramyxovirus entry, and constitute excellent research
tools for dissecting the molecular mechanisms of viral entry.
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